Meeting
2022 ASCO Annual Meeting
Do we need postoperative chemotherapy after preoperative FOLFIRINOX in resected borderline or locally advanced pancreatic cancer? A retrospective analysis.
Authors
Roxane Mari
Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France
Roxane Mari , Jonathan Garnier , Alexandra Lapeyre-Prost , Philippe Rochigneux , Yanis Dahel , Fabrice Caillol , Marc Giovannini , Olivier Turrini , Emmanuel Mitry , Brice Chanez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4150)
DOI
10.1200/JCO.2022.40.16_suppl.4150
Abstract #
4150
Poster Bd #
135
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.
First Author: Andrew Oar
Poster
2016 Gastrointestinal Cancers Symposium
Feasibility and impact on resectability of FOLFIRINOX in locally-advanced and borderline pancreatic cancer.
First Author: Fabienne Portales
Poster
2015 Gastrointestinal Cancers Symposium
Role of neoadjuvant treatment regimens for locally advanced pancreatic cancer.
First Author: Mohammad Alfayez
Poster
2014 Gastrointestinal Cancers Symposium
Novel Kras-directed therapy in combination with chemotherapy for locally advanced pancreatic adenocarcinoma.
First Author: Talia Golan